Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
Basel, 28 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved ENSPRYNG® (satralizumab) for the treatment of adults and adolescents from 12 ye
Roche's arthritis drug gets authorized as COVID-19 treatment for the severely ill
08:30am, Friday, 25'th Jun 2021
Shares of Roche Holding Group were up 0.1% in trading on Friday, the day after the company said its COVID-19 drug has been authorized in the U.S. as a treatment for those who have been hospitalized wi
FDA Gives Emergency Use Nod For Roche's Arthritis Drug Against Severe COVID-19
08:19am, Friday, 25'th Jun 2021
The FDA has approved Roche Holding AG's (OTC:RHHBY) arthritis drug Actemra (tocilizumab) for emergency use to treat adults and pediatric patients hospitalized with COVID-19. It was already allowed
Basel, 25 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActe
Genentech's Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children
07:15pm, Thursday, 24'th Jun 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has issued an Emerge
Roche's (RHHBY) BLA for PDS With Ranibizumab Accepted by FDA
01:32pm, Thursday, 24'th Jun 2021
The FDA accepts and grants Priority Review to Roche's (RHHBY) application for Port Delivery System with ranibizumab for the treatment of nAMD.
Basel, 24 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA), under Priorit
Alzheimer's Approval Validates Biopharmaceutical Innovation
06:49am, Sunday, 20'th Jun 2021
FDA approval of Biogen's Aduhelm for Alzheimer's should be broadly supportive of biotechnology and pharmaceutical stocks as it signals the agency is willing to be flexible to make important drugs. The
Roche's New COVID-19 Point Of Care Test Scores FDA Emergency Use Nod
01:27pm, Friday, 18'th Jun 2021
The FDA has granted Emergency Use Authorization (EUA) to Roche Holding AG's (OTC: RHHBY) Cobas SARS-CoV-2 Nucleic acid test for use on the Cobas Liat System. This singleplex test is the first real
BASEL, Switzerland, June 18, 2021 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for
Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche
09:26am, Wednesday, 16'th Jun 2021
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license agreement with Roche Holding AG (OTC
Roche data at EAN 2021 showcase significant impact of therapies across diverse neuroscience portfolio
01:00am, Tuesday, 15'th Jun 2021
Basel, 15 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that data across its growing neuroscience portfolio will be presented at the 7th Congress of the European Academy of Neurology
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the latest data from three pivotal Phase III studies of Venclexta® (
Basel, 11 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new interim data from two studies of Evrysdi® (risdiplam); JEWELFISH and RAINBOWFISH. Data from JEWELFISH, an ongoing open-lab
Roche obtains CE mark for the SARS-CoV-2 Antigen Self Test Nasal allowing for rapid self testing of COVID-19 at home
01:00am, Tuesday, 08'th Jun 2021
Basel, 08 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has received CE mark for its SARS-CoV-2 Antigen Self Test Nasal for at-home testing. The test will be available in countries
